1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Step Pharma Set To Leap Into Clinic With CTPS1 Inhibitor

French Biotech Raises €35m

 
• By Kevin Grogan

After a fresh cash injection, Step is ready to take STP938 for the treatment of T-cell blood cancers into Phase I trials in February.

Parker Andrew 1200
Andrew Parker • Source: Step Pharma

Step Pharma has taken a big stride towards getting its first-in-class CTPS1 inhibitor into the clinic after closing a €35m series B financing.

The French biotech, which raised €14.5m with its series A in 2017, has attracted a couple of new backers in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.